Abstract:Background Doxorubicin is one of the most effective chemotherapeutic drugs for breast cancer while its common drug resistance leads to poor patient prognosis and survival. Growing evidence indicate dynamically reorganized chromatin allows rapid access of the gene regulatory machinery to open genomic regions facilitating subsequent gene expression through direct transcription factor (TF) activation and regulatory element binding. Methods To better understand the regulatory network underlying doxorubicin resistance in breast cancer cells, we explored the systematic alterations of chromatin accessibility and gene expression by the assay for transposase-accessible chromatin using sequencing (ATAC-seq) in combination with RNA sequencing, followed by integrative analysis to identify potential regulators and their targets associated with differentially accessible regions (DARs) in doxorubicin-resistant MCF7 (MCF7-DR) cells. Results A total of 3,963 differentially expressed genes (DEGs) related to doxorubicin resistance were identified, including dramatically up-regulated MT1E , GSTP1 , LDHB , significantly down-regulated TFF1 , UBB , DSCAM-AS1 , and histone-modifying enzyme coding genes HDAC2 , EZH2 , PRMT5 , etc. By integrating with transcriptomic datasets, we identified 18,228 DARs in MCF7-DR cells compared to control, which were positively correlated with their nearest DEGs ( r = 0.6). There were 11,686 increased chromatin-accessible regions, which were enriched in up-regulated genes related to diverse KEGG pathways, such as the cell cycle, regulation of actin cytoskeleton, signaling pathways of MAPK, PI3K/Akt and Hippo, which play essential roles in regulating cell apoptosis, proliferation, metabolism, and inflammatory responses. The 6,542 decreased chromatin-accessible regions were identified for the declined doxorubicin-associated biological processes, for instance, endocrine and insulin resistance, central carbon metabolism, signaling pathways of TGF-beta and P53. Combining data from TCGA, analyses of the DAR sequences associated with the DNA-binding motifs of significantly enriched TF families including AP-1, TEAD and FOX, indicated that the loss-function of FOXA1 might play a critical role in doxorubicin-resistant breast cancer cells (DOX-R BCCs). Conclusion These data exhibit the non-genetic landscape of chromatin accessibility and transcript levels in the DOX-R BCCs, and provide clear insights and resources for the detection of critical TFs and potential cis -regulatory elements-based putative therapeutic targets.

Resistin confers resistance to doxorubicin-induced apoptosis in human breast cancer cells through autophagy induction.

Knockdown of Eukaryotic Translation Initiation Factor 5A2 Enhances the Therapeutic Efficiency of Doxorubicin in Hepatocellular Carcinoma Cells by Triggering Lethal Autophagy

Corrigendum: STAT5a Confers Doxorubicin Resistance to Breast Cancer by Regulating ABCB1

Resistin Induces Multidrug Resistance In Myeloma By Inhibiting Cell Death And Upregulating Abc Transporter Expression

Hsa_circ_0092276 Promotes Doxorubicin Resistance In Breast Cancer Cells By Regulating Autophagy Via Mir-348/Atg7 Axis

Apatinib-induced NF-κB Inactivation Sensitizes Triple-Negative Breast Cancer Cells to Doxorubicin.

Blockage of AMPK-ULK1 pathway mediated autophagy promotes cell apoptosis to increase doxorubicin sensitivity in breast cancer (BC) cells: an in vitro study

Resveratrol Attenuates Doxorubicin-Induced Cardiomyocyte Apoptosis in Mice Through SIRT1-mediated Deacetylation of P53

Src/Stat3-Dependent Heme Oxygenase-1 Induction Mediates Chemoresistance of Breast Cancer Cells to Doxorubicin by Promoting Autophagy

Doxorubicin resistance in breast cancer is mediated via the activation of FABP5/PPARγ and CaMKII signaling pathway

Integrated Chromatin Accessibility and Transcriptome Landscapes of Doxorubicin-Resistant Breast Cancer Cells

Ghrelin Inhibits Doxorubicin Cardiotoxicity by Inhibiting Excessive Autophagy Through AMPK and P38-Mapk.

ANLN Directly Interacts with RhoA to Promote Doxorubicin Resistance in Breast Cancer Cells

Role of Autophagy and Lysosomal Drug Sequestration in Acquired Resistance to Doxorubicin in MCF-7 Cells.

Exosome-Mediated Transfer of miR-3613-5p Enhances Doxorubicin Resistance by Suppression of PTEN Expression in Breast Cancer Cells

Resveratrol Attenuates Doxorubicin-Induced Cardiomyocyte Apoptosis in Lymphoma Nude Mice by Heme Oxygenase-1 Induction

Insights into the involvement of long non-coding RNAs in doxorubicin resistance of cancer

Fatty acid oxidation and autophagy promote endoxifen resistance and counter the effect of AKT inhibition in ER-positive breast cancer cells

Human resistin in chemotherapy-induced heart failure in humanized male mice and in women treated for breast cancer

Immunological roles for resistin and related adipokines in obesity-associated tumors